What are the guidelines for using Pneumococcal Polysaccharide Vaccine (PPSV23) in a healthy 1-2 year old child who has received three prior doses of Pneumococcal Conjugate Vaccine (PCV), considering the introduction of PCV20?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

PPSV23 is NOT Recommended for Healthy 1-2 Year Olds After PCV Vaccination

For a healthy child aged 1-2 years who has received three prior doses of PCV (whether PCV13 or PCV20), PPSV23 is not indicated—complete the fourth dose of pneumococcal conjugate vaccine at 12-15 months and no further pneumococcal vaccination is needed. 1, 2

Standard Schedule for Healthy Children

The ACIP guidelines are clear that healthy children require only the 4-dose PCV series without any PPSV23:

  • Complete the conjugate vaccine series: A child who received 3 doses before 12 months should receive their fourth dose at 12-15 months, at least 8 weeks after the third dose 1
  • No PPSV23 needed: Healthy children who complete the 4-dose PCV series maintain protection throughout childhood without requiring PPSV23 or booster doses after age 5 years 2
  • PCV20 consideration: While PCV20 is newer than the 2010 guidelines, the same principle applies—complete the conjugate vaccine series appropriate for the child's age, and healthy children do not require polysaccharide vaccine 2

When PPSV23 IS Indicated in Children

PPSV23 is reserved exclusively for high-risk children aged ≥2 years with specific medical conditions 1, 3:

  • Immunocompromising conditions (HIV infection, chronic renal failure, nephrotic syndrome, immunosuppressive therapy, malignancy) 3, 2
  • Anatomic or functional asplenia (including sickle cell disease) 3, 4
  • Cochlear implants 3, 4
  • Cerebrospinal fluid leaks 3, 4

Critical Timing for High-Risk Children

If your patient develops a high-risk condition, the sequence matters:

  • Always give PCV13 first, then PPSV23 at least 8 weeks later 3, 5
  • For high-risk children aged 24-71 months who received <3 doses of PCV before age 24 months: give 2 doses of PCV13 (8 weeks apart), then PPSV23 at least 8 weeks after the final PCV13 dose 3, 2
  • Never reverse this order: Giving PPSV23 before PCV13 can impair the subsequent response to PCV13 due to hyporesponsiveness 1, 3

Common Pitfalls to Avoid

  • Do not give PPSV23 to healthy children <2 years: It is neither immunogenic nor indicated in this population 1, 2
  • Do not confuse "incomplete series" with "needs PPSV23": An incomplete PCV series means completing the conjugate vaccine doses, not adding PPSV23 1
  • Do not assume all children need both vaccines: The vast majority of healthy children only need the PCV series 2

Algorithm for Your 1-2 Year Old Patient

  1. Verify vaccination history: Count total PCV doses received
  2. Assess health status: Is the child healthy or do they have high-risk conditions?
  3. If healthy with 3 prior doses: Give fourth PCV dose at 12-15 months (≥8 weeks after dose 3), then done 1
  4. If high-risk: Complete PCV series first, then add PPSV23 at age ≥2 years, ≥8 weeks after final PCV dose 3, 2

The introduction of PCV20 does not change this fundamental principle: healthy children complete their conjugate vaccine series and do not require polysaccharide vaccine 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pediatric Pneumococcal Vaccination Schedule

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pneumococcal Vaccination for Asplenic Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pneumococcal Conjugate Vaccine Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Can I give Pneumococcal Conjugate Vaccine 20 (PCV20) as the 4th dose to a healthy child between 1 to 2 years old who has already received the first three doses of a pneumococcal conjugate vaccine?
What is the difference between the pneumococcal (Streptococcus pneumoniae) conjugate vaccine and polysaccharide vaccine?
Can the Prevnar 20 (Pneumococcal conjugate vaccine) be administered early?
Can Pneumococcal Conjugate Vaccine 20 (PCV20) be administered to a healthy infant at 6 weeks, 10 weeks, and 14 weeks of age?
What is the recommended pneumococcal conjugate vaccine (PCV) schedule for a healthy infant starting from 6 weeks of age in the United States?
What is the cause and management of bradycardia in a patient with increased intracranial pressure (ICP)?
Can I give Pneumococcal Conjugate Vaccine 20 (PCV20) as the 4th dose to a healthy child between 1 to 2 years old who has already received the first three doses of a pneumococcal conjugate vaccine?
For a patient with intermediate or advanced hepatocellular carcinoma (HCC), which treatment should be started first, Transarterial Chemoembolization (TACE) or Lenvatinib (Lenvatinib)?
Can postmenopausal women with a history of osteoporosis safely use Prolia (denosumab) as maintenance medication for more than 10 years?
What are the contraindications for scopolamine, especially in geriatric patients or those with a history of narrow-angle glaucoma, myasthenia gravis, obstructive uropathy, gastrointestinal obstruction, cardiovascular disease, or dementia?
What is the recommended dosage of intravenous (IV) Levetiracetam (Keppra) for a patient with seizures or epilepsy, considering factors such as renal function and severity of seizures?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.